E-resources
Peer reviewed
Open access
-
Olszewski, Adam J; Jakobsen, Lasse H; Collins, Graham P; Cwynarski, Kate; Bachanova, Veronika; Blum, Kristie A; Boughan, Kirsten M; Bower, Mark; Dalla Pria, Alessia; Danilov, Alexey; David, Kevin A; Diefenbach, Catherine; Ellin, Fredrik; Epperla, Narendranath; Farooq, Umar; Feldman, Tatyana A; Gerrie, Alina S; Jagadeesh, Deepa; Kamdar, Manali; Karmali, Reem; Kassam, Shireen; Kenkre, Vaishalee P; Khan, Nadia; Kim, Seo-Hyun; Klein, Andreas K; Lossos, Izidore S; Lunning, Matthew A; Martin, Peter; Martinez-Calle, Nicolas; Montoto, Silvia; Naik, Seema; Palmisiano, Neil; Peace, David; Phillips, Elizabeth H; Phillips, Tycel J; Portell, Craig A; Reddy, Nishitha; Santarsieri, Anna; Sarraf Yazdy, Maryam; Smeland, Knut B; Smith, Scott E; Smith, Stephen D; Sundaram, Suchitra; Zayac, Adam S; Zhang, Xiao-Yin; Zhu, Catherine; Cheah, Chan Y; El-Galaly, Tarec C; Evens, Andrew M
Journal of clinical oncology, 04/2021, Volume: 39, Issue: 10Journal Article
Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed and validated a novel prognostic index specific for BL to aid risk stratification, interpretation of clinical trials, and targeted development of novel treatment approaches. We derived the BL International Prognostic Index (BL-IPI) from a real-world data set of adult patients with BL treated with immunochemotherapy in the United States between 2009 and 2018, identifying candidate variables that showed the strongest prognostic association with progression-free survival (PFS). The index was validated in an external data set of patients treated in Europe, Canada, and Australia between 2004 and 2019. In the derivation cohort of 633 patients with BL, age ≥ 40 years, performance status ≥ 2, serum lactate dehydrogenase > 3× upper limit of normal, and CNS involvement were selected as equally weighted factors with an independent prognostic value. The resulting BL-IPI identified groups with low (zero risk factors, 18% of patients), intermediate (one factor, 36% of patients), and high risk (≥ 2 factors, 46% of patients) with 3-year PFS estimates of 92%, 72%, and 53%, respectively, and 3-year overall survival estimates of 96%, 76%, and 59%, respectively. The index discriminated outcomes regardless of HIV status, stage, or first-line chemotherapy regimen. Patient characteristics, relative size of the BL-IPI groupings, and outcome discrimination were consistent in the validation cohort of 457 patients, with 3-year PFS estimates of 96%, 82%, and 63% for low-, intermediate-, and high-risk BL-IPI, respectively. The BL-IPI provides robust discrimination of survival in adult BL, suitable for use as prognostication and stratification in trials. The high-risk group has suboptimal outcomes with standard therapy and should be considered for innovative treatment approaches.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.